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Recent experience has prompted the US FDA to consider
whether ethanol ingestion may modify the release characteristics
of prolonged-release formulations, where dose dumping may be
an issue for patient safety.
The influence of ethanol on the in vitro release of opioid drugs
from some prolonged-release formulations utilizing different
release technologies was examined. Results indicated that the
prolonged-release mechanisms remained intact under the testing
conditions, although one product showed initial sensitivity to eth-
anol in its release characteristics. Nevertheless, in this case,
extrapolation of the findings to likely outcome in vivo indicated no
risk of dose-dumping.
It is proposed that prolonged-release medicinal products
should be tested during development to ensure robustness to the
effects of ethanol on drug release.
Keywords prolonged-release; opioid; hydromorphone; in vitro disso-
lution rate; ethanol (or alcohol) testing; pharmacokinetics
INTRODUCTION
Since their introduction in the 1980’s, oral prolonged-release
opioid formulations have been a mainstay in the management of
moderate to severe pain, particularly that due to cancer. MST®
Continus® tablets were introduced to provide a controlled deliv-
ery of morphine over 12 h. This was followed by 12 h release
formulations of hydromorphone (Palladone® SR capsules), oxy-
codone (OxyContin® tablets), dihydrocodeine (DHC® Continus
tablets), and tramadol (Zydol® SR tablets, Dromadol® SR tab-
lets, and Zamadol SR capsules). Subsequently, preparations pro-
viding the delivery of morphine (MXL® capsules, Morcap SR
capsules) and tramadol (Zydol XL tablets) over a 24 h period
were developed, enabling the management of pain with a conve-
nient once-daily dosing regimen.
As these formulations contain a larger unit dose than con-
ventional, immediate release tablets, which are intended for 4−6
hourly administration, it is imperative that their retardation
properties are tightly controlled. This is to ensure that a rapid
release of the drug (“dose-dumping”) cannot occur. Prolonged-
release formulations are subject to stringent limits on in vitro
dissolution to ensure a consistent batch-to-batch uniformity of
the finished product. In addition, studies are conducted in
healthy volunteers to investigate the influence of a high-fat
meal, and the associated delayed gastric emptying, on the
in vivo release characteristics of each formulation, to ensure
that the prolonged delivery of the active moiety is maintained,
regardless of dietary status.
Some oral prolonged-release dosage forms contain drugs
and excipients that exhibit a higher solubility in aqueous solu-
tions containing ethanol. Accordingly, such products may be
expected to exhibit more rapid drug dissolution and release in
the presence of ingested ethanol. Recently, a once-daily formu-
lation of hydromorphone was withdrawn from the US market
following concern over the potential for ethanol-induced dose-
dumping. The manufacturers had been prompted to conduct a
pharmacokinetic study by the results of an in vitro evaluation
of the dissolution of the preparation in different concentrations
of ethanol. The results of the latter evaluation are presented in
Figure 1, showing a more rapid release of hydromorphone in
increasing concentrations of ethanol in aqueous solution.
In a subsequent pharmacokinetic study, healthy subjects were
protected from the effects of the opioid agonist by naltrexone
blockade (HMP1013). Each subject received a single prolonged-
release capsule, containing 12 mg of hydromorphone hydrochlo-
ride, according to a randomised, crossover design, including a
control arm (no ethanol) and 3 arms involving the ingestion of
240 mL of varying concentrations of ethanol immediately before
the once-daily hydromorphone prolonged-release capsule.
Address correspondence to Malcolm Walden, Mundipharma
Research Limited, Cambridge Science Park, Milton Road, Cambridge,
CB4 0GW, UK. E-mail: Malcolm.Walden@mundipharma-rd.eu1102 M. WALDEN ET AL.
The two higher concentrations of ethanol represented the equiv-
alent of drinking one-third of a bottle of spirit or one-third of a
bottle of fortified wine, respectively, over an approximately 5
min period. The results are summarised in Table 1.
On average, there was a 26% increase in the AUC of hydro-
morphone when administered following the ingestion of 40%
ethanol. The maximum systemic exposure, as indicated by
Cmax values, and, therefore, the rate of hydromorphone absorp-
tion, was increased markedly in some individuals, particularly
at the higher concentration of ethanol. After the ingestion of
40% ethanol, the mean increase in Cmax was 5.5-fold, with one
individual showing a 16-fold increase.
These findings were confirmed in a subsequent study
(HMP1014), which also showed that the ingestion of ethanol
either 3 h before or 4 h after the administration of the once-
daily prolonged-release hydromorphone capsule had no effect
on the kinetics of the opioid, thereby providing guidance on the
time period within which the drug preparation and ethanol
should not be taken together.
It was recognised that the most extreme test treatment,
equating to ingestion of up to the equivalent of one-third of a
bottle of spirit taken over only 5 min, represented an extreme
challenge to the formulation. Nevertheless, the once-daily
prolonged-release hydromorphone capsule was withdrawn vol-
untarily by the manufacturer, removing any potential risk to
patients of inadvertent dose-dumping.
This recent experience has prompted the US FDA to con-
sider further the issue of whether ethanol ingestion may modify
the release characteristics of new and currently marketed pro-
longed-release formulations. The main objective of such an
approach will be to minimize the risk of ethanol-induced dose
dumping, irrespective of any warnings on product labelling and
instructions by health care providers (Meyer & Hussain, 2005).
Clearly, the risk is accentuated for products containing drugs
that have a narrow therapeutic margin, or those containing
drugs such as potent opioids where careful titration of dose to
effect is necessary.
FIGURE 1. Cumulative release of hydromorphone from hydromorphone once daily capsules in simulated gastric fluid/ethanol.
TABLE 1 
The Effect of Different Concentrations of Ethanol on Systemic 
Exposure to Hydromorphone After Administration of 12 mg in 
Hydromorphone Once-Daily Capsules
Ethanol
Concentration
(% v/v)
Mean Cmax Ratio
(and range)
(Relative to Control
No Ethanol)
Mean AUC Ratio
(and Range)
(Relative to Control
No ethanol)
40 5.53 (0.77–15.8) 1.26 (0.61–3.35)
20 1.89 (0.76–5.72) 0.96 (0.41–1.46)
4 1.06 (0.73–1.96) 1.00 (0.48–1.85)
Cmax=maximum plasma drug concentration; AUC=total area under
the plasma drug concentration—time curve.ETHANOL EFFECT ON ORAL PROLONGED-RELEASE OPIOIDS 1103
However, evaluating the consequences of co-ingestion of
high doses of ethanol together with prolonged-release formula-
tions in healthy subjects is also not without risk, even in the
case of opioids where the co-administration of an opioid antag-
onist is also feasible. A potential regulatory approach could be
to require a standard series of in vitro dissolution tests to estab-
lish that the drug-release characteristics of the originator prod-
uct or generic product are robust in the presence of ethanol.
Against this background, the present investigation exam-
ined the influence of high concentrations of ethanol on the in
vitro release properties of a range of prolonged-release opioid
formulations which utilise a variety of different release tech-
nologies (matrix control (monolithic and multiparticulate), ion-
exchange, coated beads).
METHODS
The effect of ethanol on drug release from the products
listed in Table 2 was evaluated by the corresponding dissolu-
tion tests used routinely for quality control. Some of these tests
simulate stomach pH while others simulate the average pH in
the small intestine. Standard dissolution testing equipment
defined in pharmacopoeial monographs was used. The dissolu-
tion media were modified by replacing appropriate volumes of
the standard aqueous media with volumes of ethanol to pro-
duce solutions with ethanol concentrations up to 40% v/v. This
upper limit was chosen as it represents a standard strength of
spirits. It is recognized that, in vivo, the ingestion of spirits in
such concentration will be subject to immediate dilution by the
residual volume of the stomach (typically 50 mL in the fasting
state) with further dilution over time due to gastric secretion,
the intake of food and fluid, and the absorption and metabolism
of ethanol in the stomach. Thus, in vitro experiments with con-
centrations of 40% ethanol over a 2 h period are expected to be
representative of the most extreme conditions likely to be
encountered in vivo.
To offset the effects of chromatographic differences and
different rates of evaporation of the modified media, standards
used to assay the drugs were maintained at 37°C and prepared
with the same media as used in each dissolution test. At least
two representative unit doses of each formulation were tested
in each case and the mean values of cumulative release were
calculated. Drug concentrations were measured by reversed
phase HPLC with UV detection at an appropriate wavelength.
All of the drug assays were validated to ICH guidelines for
specificity, linearity, accuracy and precision.
RESULTS
Cumulative release profiles for each of the products tested
are shown in Figures 2 to 10. The results for most of the prod-
ucts indicated a negligible effect of ethanol on the release of
the active ingredient. Palladone SR capsules, which utilise a
coated bead technology, demonstrate a distinct biphasic effect
as a function of ethanol concentration–the initial drug release
rate decreased as the ethanol concentration was increased from
5 to 15% v/v then increased to control values at 30% v/v with a
further increase compared to control values at 35−40% v/v. To
provide confidence in this observation, the experiment was
repeated using a different batch of Palladone SR capsules and
taking the mean result for 6 separate capsules at alcohol con-
centrations of 10, 30, and 40% v/v. The effect of ethanol on the
pattern of drug release was confirmed, and the maximum coef-
ficient of variation of drug release within unit doses across all
sampling points was 3%.
DISCUSSION
Experience with the once-daily hydromorphone preparation
has highlighted the potential for ethanol to alter the retardation
properties of prolonged-release formulations. The exact effect
will depend upon gastric emptying time, the absorption and
metabolism of ethanol in the stomach, fluid secretion into the
stomach and the nature of the formulation.
Normally, the gastric emptying of liquids is rapid with a
half time of 12 min, such that 95% is emptied in 1 h (Petring &
Blake).
Levitt et al. (1997) found that, in fasted individuals, 90% of
a 0.15 g/kg dose of ethanol had emptied from the stomach by
20–30 min, with the remainder being absorbed from the stom-
ach in this time. In the fed state a half-time of 50 min for liquid
emptying was reported, with about 70% of the ethanol passing
into the duodenum after 2h and 30% absorbed from the
stomach.
Franke et al. (2004) reported that pure ethanol inhibited gas-
tric emptying. Mean half-emptying times of 22.6, 22.7 and
27.8 min, with ethanol solutions of 4%, 10% and 40% respec-
tively were significantly longer than those after ingestion of
water (14.6 min). Moreover, the inhibitory effects of beer (half
emptying time of 39.3 min) and red wine (half emptying time
of 72.6 min), but not of whisky (half emptying time of 26.4
min), were greater than those of their comparable ethanol
concentrations. This suggested that the caloric content and
non-ethanolic ingredients in ethanolic beverages produced by
fermentation, but not those produced by distillation, were also
partly responsible for this effect.
Oneta et al. (1998) indicate that a delay in gastric emptying
increases exposure of ethanol to gastric ethanol dehydroge-
nase, thereby increasing its metabolism.
Basal gastric secretion rates of up to 3 L/day (125 mL/h)
have been reported Freitas (1999). Thus, there will be a signifi-
cant dilution of any ethanol in the stomach with time. It should
also be noted that ethanol undergoes rapid absorption once it is
emptied from the stomach and this will curtail any continuing
effect on drug release from a prolonged-release formulation
(Roine et al., 1991).
Recognizing the above variables, it was considered that in
vitro dissolution studies over 2 h with ethanol concentrations
of up to 40%v/v should afford confidence with regard to theT
A
B
L
E
 
2
 
P
r
o
d
u
c
t
s
 
D
e
t
a
i
l
s
A
c
t
i
v
e
 
I
n
g
r
e
d
i
e
n
t
F
o
r
m
u
l
a
t
i
o
n
 
T
e
c
h
n
o
l
o
g
y
/
E
x
c
i
p
i
e
n
t
s
D
i
s
s
o
l
u
t
i
o
n
 
M
e
d
i
u
m
D
i
s
s
o
l
u
t
i
o
n
M
e
t
h
o
d
D
H
C
®
 
C
o
n
t
i
n
u
s
®
 
1
2
0
 
m
g
 
t
a
b
l
e
t
s
*
D
i
h
y
d
r
o
c
o
d
e
i
n
e
 
t
a
r
t
r
a
t
e
C
O
N
T
I
N
U
S
®
 
m
a
t
r
i
x
 
c
o
n
t
r
o
l
L
a
c
t
o
s
e
,
 
c
e
t
o
s
t
e
a
r
y
l
 
a
l
c
o
h
o
l
,
 
t
a
l
c
,
 
h
y
d
r
o
x
y
e
t
h
y
l
c
e
l
l
u
l
o
s
e
,
 
m
a
g
n
e
s
i
u
m
 
s
t
e
a
r
a
t
e
P
h
o
s
p
h
a
t
e
 
b
u
f
f
e
r
 
p
H
 
6
.
5
 
P
h
.
 
E
u
r
.
 
F
o
r
 
e
a
c
h
 
l
i
t
r
e
 
d
i
s
s
o
l
v
e
 
i
n
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
:
6
.
8
0
5
 
g
 
p
o
t
a
s
s
i
u
m
 
d
i
h
y
d
r
o
g
e
n
 
o
r
t
h
o
p
h
o
s
p
h
a
t
e
 
(
A
R
)
,
 
0
.
5
6
 
g
 
s
o
d
i
u
m
 
h
y
d
r
o
x
i
d
e
 
(
A
R
)
.
 
P
u
r
g
e
 
w
i
t
h
 
h
e
l
i
u
m
;
p
H
 
t
o
 
6
.
5
 
±
 
0
.
0
5
.
P
a
d
d
l
e
s
1
0
0
 
±
 
4
 
r
p
m
9
0
0
 
m
L
3
7
°
C
M
S
T
®
 
C
o
n
t
i
n
u
s
®
 
2
0
0
 
m
g
s
u
s
p
e
n
s
i
o
n
*
M
o
r
p
h
i
n
e
 
s
u
l
p
h
a
t
e
C
o
n
t
r
o
l
l
e
d
 
(
I
o
n
 
e
x
c
h
a
n
g
e
)
 
r
e
l
e
a
s
e
 
g
r
a
n
u
l
e
s
 
i
n
 
s
a
c
h
e
t
s
M
o
d
i
f
i
e
d
 
U
S
P
 
s
i
m
u
l
a
t
e
d
 
g
a
s
t
r
i
c
 
f
l
u
i
d
 
(
n
o
 
p
e
p
s
i
n
)
.
 
F
o
r
 
e
a
c
h
 
l
i
t
r
e
 
d
i
s
s
o
l
v
e
 
2
.
0
 
G
 
o
f
 
s
o
d
i
u
m
 
c
h
l
o
r
i
d
e
 
(
A
R
)
 
i
n
 
5
0
0
 
m
L
 
o
f
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
.
 
A
d
d
 
7
.
0
 
m
L
 
o
f
 
c
o
n
c
e
n
t
r
a
t
e
d
 
h
y
d
r
o
c
h
l
o
r
i
c
 
a
c
i
d
,
 
d
i
s
s
o
l
v
e
 
a
n
d
 
m
a
k
e
 
t
o
 
1
 
l
i
t
r
e
 
w
i
t
h
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
.
 
P
u
r
g
e
 
w
i
t
h
 
h
e
l
i
u
m
;
 
p
H
 
t
o
 
1
.
1
 
±
 
0
.
0
5
.
P
a
d
d
l
e
s
 
1
0
0
 
±
 
4
 
r
p
m
C
a
t
i
o
n
i
c
 
e
x
c
h
a
n
g
e
 
r
e
s
i
n
,
 
x
a
n
t
h
a
n
g
u
m
,
 
P
o
n
c
e
a
u
 
4
R
 
(
E
1
2
4
)
,
x
y
l
i
t
o
l
,
 
r
a
s
p
b
e
r
r
y
 
f
l
a
v
o
u
r
9
0
0
 
m
L
3
7
°
C
M
S
T
®
 
C
o
n
t
i
n
u
s
®
 
1
0
0
 
m
g
 
t
a
b
l
e
t
s
*
M
o
r
p
h
i
n
e
 
s
u
l
p
h
a
t
e
C
O
N
T
I
N
U
S
®
 
m
a
t
r
i
x
 
c
o
n
t
r
o
l
L
a
c
t
o
s
e
,
 
c
e
t
o
s
t
e
a
r
y
l
 
a
l
c
o
h
o
l
,
 
t
a
l
c
,
 
h
y
d
r
o
x
y
e
t
h
y
l
c
e
l
l
u
l
o
s
e
,
 
m
a
g
n
e
s
i
u
m
 
s
t
e
a
r
a
t
e
P
h
o
s
p
h
a
t
e
 
b
u
f
f
e
r
 
p
H
 
6
.
5
 
P
h
.
 
E
u
r
.
 
F
o
r
 
e
a
c
h
 
l
i
t
r
e
 
d
i
s
s
o
l
v
e
 
i
n
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
:
 
6
.
8
0
5
 
g
 
p
o
t
a
s
s
i
u
m
 
d
i
h
y
d
r
o
g
e
n
 
o
r
t
h
o
p
h
o
s
p
h
a
t
e
 
(
A
R
)
,
 
0
.
5
6
 
g
 
s
o
d
i
u
m
 
h
y
d
r
o
x
i
d
e
 
(
A
R
)
.
 
P
u
r
g
e
 
w
i
t
h
 
H
e
l
i
u
m
;
 
p
H
 
t
o
 
6
.
5
 
±
 
0
.
0
5
.
P
a
d
d
l
e
s
 
1
0
0
 
±
 
4
 
r
p
m
9
0
0
 
m
L
3
7
°
C
M
X
L
®
 
2
0
0
 
m
g
 
c
a
p
s
u
l
e
s
*
M
o
r
p
h
i
n
e
 
s
u
l
p
h
a
t
e
M
a
t
r
i
x
 
p
r
o
l
o
n
g
e
d
-
r
e
l
e
a
s
e
 
m
u
l
t
i
p
a
r
t
i
c
u
l
a
t
e
s
P
h
o
s
p
h
a
t
e
 
b
u
f
f
e
r
 
p
H
 
6
.
5
 
P
h
.
 
E
u
r
.
 
F
o
r
 
e
a
c
h
 
l
i
t
r
e
 
d
i
s
s
o
l
v
e
 
i
n
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
:
 
6
.
8
0
5
g
 
p
o
t
a
s
s
i
u
m
 
d
i
h
y
d
r
o
g
e
n
 
o
r
t
h
o
p
h
o
s
p
h
a
t
e
 
(
A
R
)
,
 
0
.
5
6
g
 
s
o
d
i
u
m
 
h
y
d
r
o
x
i
d
e
 
(
A
R
)
.
 
P
u
r
g
e
 
w
i
t
h
 
H
e
l
i
u
m
;
 
p
H
 
t
o
 
6
.
5
 
±
 
0
.
0
5
P
a
d
d
l
e
s
 
1
0
0
 
±
 
4
 
r
p
m
H
y
d
r
o
g
e
n
a
t
e
d
 
v
e
g
e
t
a
b
l
e
 
o
i
l
,
 
p
o
l
y
e
t
h
y
l
e
n
e
 
g
l
y
c
o
l
,
 
m
a
g
n
e
s
i
u
m
 
s
t
e
a
r
a
t
e
,
 
t
a
l
c
9
0
0
 
m
L
3
7
°
C
O
x
y
C
o
n
t
i
n
®
 
8
0
 
m
g
 
t
a
b
l
e
t
s
*
O
x
y
c
o
d
o
n
e
 
h
y
d
r
o
c
h
l
o
r
i
d
e
A
C
R
O
C
O
N
T
I
N
®
 
m
a
t
r
i
x
 
c
o
n
t
r
o
l
L
a
c
t
o
s
e
 
m
o
n
o
h
y
d
r
a
t
e
,
 
g
l
y
c
e
r
y
l
 
t
r
i
a
c
e
t
a
t
e
,
 
t
a
l
c
,
 
a
m
m
o
n
i
o
m
e
t
h
a
c
r
y
l
a
t
e
 
p
o
l
y
m
e
r
,
 
p
o
v
i
d
o
n
e
,
 
s
t
e
a
r
y
l
 
a
l
c
o
h
o
l
,
 
m
a
g
n
e
s
i
u
m
 
s
t
e
a
r
a
t
e
M
o
d
i
f
i
e
d
 
U
S
P
 
s
i
m
u
l
a
t
e
d
 
g
a
s
t
r
i
c
 
f
l
u
i
d
 
(
n
o
 
p
e
p
s
i
n
)
.
F
o
r
 
e
a
c
h
 
l
i
t
r
e
 
d
i
s
s
o
l
v
e
 
2
.
0
 
g
 
o
f
 
s
o
d
i
u
m
 
c
h
l
o
r
i
d
e
(
A
R
)
 
i
n
 
5
0
0
 
m
L
 
o
f
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
.
 
A
d
d
 
7
.
0
 
m
L
o
f
 
c
o
n
c
e
n
t
r
a
t
e
d
 
h
y
d
r
o
c
h
l
o
r
i
c
 
a
c
i
d
;
 
d
i
s
s
o
l
v
e
 
a
n
d
m
a
k
e
 
t
o
 
1
 
l
i
t
r
e
 
w
i
t
h
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
.
 
P
u
r
g
e
 
w
i
t
h
 
H
e
l
i
u
m
;
 
p
H
 
t
o
 
1
.
2
 
±
 
0
.
1
.
U
S
P
 
A
p
p
a
r
a
t
u
s
 
1
(
B
a
s
k
e
t
)
 
1
0
0
 
±
 
4
 
r
p
m
9
0
0
 
m
L
3
7
°
CP
a
l
l
a
d
o
n
e
®
 
S
R
 
2
4
 
m
g
 
c
a
p
s
u
l
e
s
*
H
y
d
r
o
m
o
r
p
h
o
n
e
 
h
y
d
r
o
c
h
l
o
r
i
d
e
C
o
a
t
e
d
 
b
e
a
d
 
t
e
c
h
n
o
l
o
g
y
M
i
c
r
o
c
r
y
s
t
a
l
l
i
n
e
 
c
e
l
l
u
l
o
s
e
,
 
h
y
d
r
o
x
y
p
r
o
p
y
l
m
e
t
h
y
l
 
c
e
l
l
u
l
o
s
e
,
 
w
a
t
e
r
,
 
e
t
h
y
l
c
e
l
l
u
l
o
s
e
,
 
d
i
b
u
t
y
l
 
s
e
b
a
c
a
t
e
0
.
1
%
 
w
/
v
 
s
o
d
i
u
m
 
l
a
u
r
y
l
 
s
u
l
p
h
a
t
e
.
F
o
r
 
e
a
c
h
 
l
i
t
r
e
 
d
i
s
s
o
l
v
e
 
1
 
g
 
o
f
 
s
o
d
i
u
m
 
l
a
u
r
y
l
 
s
u
l
p
h
a
t
e
(
9
9
%
 
S
i
g
m
a
)
.
 
P
u
r
g
e
 
w
i
t
h
 
H
e
l
i
u
m
P
h
 
E
u
r
 
B
a
s
k
e
t
1
5
0
 
±
 
6
 
r
p
m
9
0
0
 
m
L
3
7
°
C
C
o
d
e
i
n
e
 
C
o
n
t
i
n
®
 
1
0
0
 
m
g
 
t
a
b
l
e
t
s
*
*
C
o
d
e
i
n
e
 
b
a
s
e
,
C
o
d
e
i
n
e
s
u
l
p
h
a
t
e
C
O
N
T
I
N
U
S
®
 
m
a
t
r
i
x
 
c
o
n
t
r
o
l
L
a
c
t
o
s
e
,
 
s
t
e
a
r
y
l
 
a
l
c
o
h
o
l
,
 
t
a
l
c
,
 
h
y
d
r
o
x
y
e
t
h
y
l
c
e
l
l
u
l
o
s
e
,
 
m
a
g
n
e
s
i
u
m
 
s
t
e
a
r
a
t
e
P
u
r
i
f
i
e
d
,
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
U
S
P
 
A
p
p
a
r
a
t
u
s
 
1
 
(
B
a
s
k
e
t
)
1
0
0
 
±
 
4
 
r
p
m
5
0
0
 
m
L
3
7
°
C
Z
a
m
a
d
o
l
®
 
2
4
 
h
 
4
0
0
 
m
g
 
t
a
b
l
e
t
s
 
(
o
n
c
e
 
d
a
i
l
y
)
*
*
*
T
r
a
m
a
d
o
l
H
y
d
r
o
c
h
l
o
r
i
d
e
M
a
t
r
i
x
 
p
r
o
l
o
n
g
e
d
-
r
e
l
e
a
s
e
 
t
a
b
l
e
t
H
y
d
r
o
g
e
n
a
t
e
d
 
v
e
g
e
t
a
b
l
e
 
o
i
l
,
 
t
a
l
c
,
 
m
a
g
n
e
s
i
u
m
 
s
t
e
a
r
a
t
e
P
h
o
s
p
h
a
t
e
 
b
u
f
f
e
r
 
p
H
 
6
.
5
 
P
h
.
 
E
u
r
.
 
F
o
r
 
e
a
c
h
 
l
i
t
r
e
 
d
i
s
s
o
l
v
e
 
i
n
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
:
6
.
8
0
5
g
 
p
o
t
a
s
s
i
u
m
 
d
i
h
y
d
r
o
g
e
n
 
o
r
t
h
o
p
h
o
s
p
h
a
t
e
 
(
A
R
)
,
 
0
.
5
6
g
 
s
o
d
i
u
m
 
h
y
d
r
o
x
i
d
e
 
(
A
R
)
.
 
P
u
r
g
e
 
w
i
t
h
 
H
e
l
i
u
m
;
 
p
H
 
t
o
 
6
.
5
 
±
 
0
.
0
5
P
a
d
d
l
e
s
 
1
0
0
 
±
 
4
 
r
p
m
9
0
0
 
m
L
3
7
°
C
D
r
o
m
a
d
o
l
®
 
S
R
 
2
0
0
 
m
g
t
a
b
l
e
t
s
 
(
t
w
i
c
e
 
d
a
i
l
y
)
*
*
*
*
T
r
a
m
a
d
o
l
 
H
y
d
r
o
c
h
l
o
r
i
d
e
M
a
t
r
i
x
 
p
r
o
l
o
n
g
e
d
-
r
e
l
e
a
s
e
 
t
a
b
l
e
t
H
y
d
r
o
g
e
n
a
t
e
d
 
v
e
g
e
t
a
b
l
e
 
o
i
l
,
 
t
a
l
c
,
 
m
a
g
n
e
s
i
u
m
 
s
t
e
a
r
a
t
e
P
h
o
s
p
h
a
t
e
 
b
u
f
f
e
r
 
p
H
 
6
.
5
 
P
h
.
 
E
u
r
.
 
F
o
r
 
e
a
c
h
 
l
i
t
r
e
 
d
i
s
s
o
l
v
e
 
i
n
 
d
e
i
o
n
i
s
e
d
 
w
a
t
e
r
:
6
.
8
0
5
g
 
p
o
t
a
s
s
i
u
m
 
d
i
h
y
d
r
o
g
e
n
 
o
r
t
h
o
p
h
o
s
p
h
a
t
e
 
(
A
R
)
,
 
0
.
5
6
g
 
s
o
d
i
u
m
 
h
y
d
r
o
x
i
d
e
 
(
A
R
)
.
 
P
u
r
g
e
 
w
i
t
h
 
H
e
l
i
u
m
;
 
p
H
 
t
o
 
6
.
5
 
±
 
0
.
0
5
P
a
d
d
l
e
s
 
1
0
0
 
±
 
4
 
r
p
m
9
0
0
 
m
L
3
7
°
C
*
M
a
r
k
e
t
e
d
 
i
n
 
t
h
e
 
U
K
 
b
y
 
N
a
p
p
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
L
i
m
i
t
e
d
.
*
*
M
a
r
k
e
t
e
d
 
i
n
 
C
a
n
a
d
a
 
b
y
 
P
u
r
d
u
e
 
P
h
a
r
m
a
 
I
n
c
.
*
*
*
M
a
r
k
e
t
e
d
 
i
n
 
t
h
e
 
U
K
 
b
y
 
M
e
d
a
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
.
*
*
*
*
M
a
r
k
e
t
e
d
 
i
n
 
t
h
e
 
U
K
 
b
y
 
T
e
v
a
 
P
h
a
r
m
a
.1106 M. WALDEN ET AL.
FIGURE 2. Cumulative release of dihydrocodeine from 120 mg DHC Continus tablets in pH 6.5 phosphate buffer/ethanol.
FIGURE 3. Cumulative release of morphine from 200 mg MST Continus suspension in simulated gastric fluid/ethanol.ETHANOL EFFECT ON ORAL PROLONGED-RELEASE OPIOIDS 1107
FIGURE 4. Cumulative release of morphine from 100 mg MST Continus tablets in simulated gastric fluid/ethanol.
FIGURE 5. Cumulative release of morphine from 200 mg MXL CR capsules in phosphate buffer/ethanol.1108 M. WALDEN ET AL.
FIGURE 6. Cumulative release of oxycodone from 80 mg OxyContin tablets in simulated gastric fluid/ethanol.
FIGURE 7.  Cumulative release of hydromorphone from Palladone SR capsules in 0.1% w/v sodium lauryl sulphate/ethanol.ETHANOL EFFECT ON ORAL PROLONGED-RELEASE OPIOIDS 1109
FIGURE 8. Cumulative release of codeine from Codeine Contin 100 mg tablets in water/ethanol.
FIGURE 9. Cumulative release of tramadol from tramadol 200 mg b.d. tablets in pH 6.5 buffer/ethanol.1110 M. WALDEN ET AL.
likelihood of altered release rate or dose-dumping consistent
with the most extreme conditions likely to be encountered
in vivo.
Of the products tested in this study, only one (Palladone SR
capsules) indicated a clear increase in dissolution rate in the
first hour in the presence of high concentrations of ethanol.
Thereafter, hydromorphone was released at a rate consistent
with that of the control, as demonstrated by the parallel slopes
of the release curves.
Simulation of the in vivo impact of this on the in vivo kinet-
ics of hydromorphone (unpublished) indicated that any
increase in peak plasma hydromorphone concentration arising
from a 2 h exposure to 40% ethanol would be expected to be of
the order of 15−30%. This change is similar in magnitude to
that commonly observed when some prolonged-release formu-
lations are compared under fed and fasting conditions. There-
fore, such an increase would not be expected to be of clinical
significance.
Figure 1 shows clearly that with the hydromorphone once a
day formulation that was withdrawn in the USA, ethanol in
concentrations up to 40%v/v had a major effect in increasing
the rate of drug release, producing a ‘dose dumping’ consistent
with the subsequent in vivo findings. This particular formula-
tion contains significant quantities of release controlling excip-
ients that are soluble in 40% v/v ethanol but not in water,
although the effect of ethanol may depend on other formulation
factors as well as discussed below.
The dissolution conditions used routinely for quality control
of the release properties of the products that we have investi-
gated differ in terms of pH and dissolution media (Table 2).
However, in order to provide a standardised testing approach,
regulatory guidance on the appropriate conditions and duration
of testing is encouraged.
The products investigated cover a variety of prolonged-
release formulation technologies and utilise a broad spectrum
of release-controlling excipients. The results have shown that
the prolonged-release mechanisms of the products remain
intact under the testing conditions. When extrapolated to the in
vivo situation, the data indicate that there is no risk of a poten-
tially dangerous dose-dumping. It is believed that the experi-
mental conditions selected, which are expected to be
representative of the most extreme conditions likely to be
encountered in vivo, were justified by our understanding of
gastric conditions and the fate of ethanol in the stomach.
Analysis of these data and unpublished confidential mate-
rial indicates that there is no clear correlation between the etha-
nol solubility of the ingredients and the ethanol susceptibility
of formulations, rather there may be complex interactions
between active and inactive ingredients and dosage form
design. Therefore, it is proposed that all prolonged-release
medicinal products should be subjected to in vitro testing dur-
ing formulation development to ensure their robustness to the
effects on drug release when consumed with alcoholic bever-
ages. This is of particular concern with preparations containing
FIGURE 10. Cumulative release of tramadol from tramadol 400 mg o.d. tablets in pH 6.5 buffer/ethanol.ETHANOL EFFECT ON ORAL PROLONGED-RELEASE OPIOIDS 1111
drugs with a narrow therapeutic index or drugs such as strong
opioids where careful titration of dosage is necessary. A stan-
dardized approach to testing needs to be agreed and adopted
internationally by the pharmaceutical industry and regulatory
authorities.
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